When Memorial Sloan-Kettering Cancer Center in New York City stopped accepting commercial support for its continuing medical education activities last January, many at the institution had their doubts that the program would survive. “Our staff was very worried that this would deep-six the CME program,” says Thomas Fahey Jr., MD, senior vice president, clinical program development at MSKCC, and chairman of the CME committee. He and others were surprised at the decision, particularly because ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to No Pharma Funding, you'll get exclusive access to a large archive of premium content.

Already registered? here.